Definitions

Sorry, no definitions found. You may find more data at morquio.

Etymologies

Sorry, no etymologies found.

Support

Help support Wordnik (and make this page ad-free) by adopting the word Morquio.

Examples

  • Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disease characterized by deficient activity of N-acetylgalactosamine-6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS).

    BioSpace.com Featured News and Stories 2010

  • Mucopolysaccharidosis IVA (MPS IVA, also known as Morquio A Syndrome) is a disorder characterized by deficient activity of N-acetylgalactosamine 6-sulfatase (GALNS) causing excessive lysosomal storage of keratan sulfate (KS).

    unknown title 2009

  • (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome.

    BioSpace.com Featured News and Stories 2010

  • We have also shown that GALNS is taken up into human Morquio chondrocytes in vitro and reaches the lysosome to clear keratan sulfate.

    SeekingAlpha.com: Home Page 2009

  • We are finding that there are a number of Morquio patients out there, a large number in the clinic, worldwide, and many are here to be treated.

    pfblogs.org: The Ad-Free Personal Finance Blogs Aggregator 2008

  • It’s called Morquio Syndrome, which is a rare form of dwarfism.

    SciFi, Fantasy & Horror Collectibles - Part 652 2009

  • BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

    THE MEDICAL NEWS 2010

  • BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

    unknown title 2009

  • announced today that its application for clinical trial authorization (CTA) for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome, has been accepted by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

    unknown title 2009

  • Jean-Jacques Bienaime, Chief Executive Officer of BioMarin added, "Based on these data, we are more optimistic about the GALNS program as we continue to move closer to providing a treatment option for Morquio patients.

    BioSpace.com Featured News and Stories 2010

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.